YD Bio Ltd (YDES) Financial Statements
YD Bio Ltd (YDES) reported trailing twelve-month revenue of $1.2M (up 16.9% year on year) and net income of -$8.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$8.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
YDESYD Bio LtdFollow YDES — free
—
Price chart with a free account
- Market cap
- 350.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- —
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 0.4 | 0.5 | 0.6 | 1.2 | |
| Gross profit | 0.2 | 0.2 | 0.2 | 0.4 | |
| Research & development | — | 0.5 | 1.6 | — | |
| Operating income | -0.0 | -1.5 | -5.3 | -6.6 | |
| Pre-tax income | 0.0 | -1.4 | -8.3 | 0.3 | |
| Income tax | 0.0 | 0.0 | -0.0 | — | |
| Net income | 0.0 | -1.4 | -8.3 | — | |
| Diluted EPS ($) | 0.00 | -0.02 | -0.12 | 0.00 | |
| Diluted shares (mn) | 64.7 | 64.7 | 66.7 | — |
USD millions · SEC XBRL
YD Bio Ltd — questions
- What is YD Bio Ltd's revenue?
- $1.2M over the twelve months to 2026-06-30, up 16.9% year on year, from its 10-Q and 10-K filings.
- What is YD Bio Ltd's net income?
- -$8.3M over the twelve months to 2026-06-30.
- What is YD Bio Ltd's free cash flow?
- -$8.7M over the twelve months to 2026-06-30.
- What are YD Bio Ltd's diluted earnings per share?
- $0.00 over the twelve months to 2026-06-30.
Every figure on this page comes from YD Bio Ltd's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.